CY1122771T1 - Φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης για τη χορηγηση πρωτεϊνων στον οφθαλμο και μεθοδοι για την παρασκευη αυτων - Google Patents

Φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης για τη χορηγηση πρωτεϊνων στον οφθαλμο και μεθοδοι για την παρασκευη αυτων

Info

Publication number
CY1122771T1
CY1122771T1 CY20201100042T CY201100042T CY1122771T1 CY 1122771 T1 CY1122771 T1 CY 1122771T1 CY 20201100042 T CY20201100042 T CY 20201100042T CY 201100042 T CY201100042 T CY 201100042T CY 1122771 T1 CY1122771 T1 CY 1122771T1
Authority
CY
Cyprus
Prior art keywords
administration
eye
sustained
proteins
preparation
Prior art date
Application number
CY20201100042T
Other languages
English (en)
Inventor
Vernon Wong
Louis Wood
Glenn Huang
Original Assignee
Ramscor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramscor, Inc. filed Critical Ramscor, Inc.
Publication of CY1122771T1 publication Critical patent/CY1122771T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ενέσιμες φαρμακοτεχνικές μορφές παρατεταμένης αποδέσμευσης για τη χορήγηση δραστικών παραγόντων, ιδιαίτερα θεραπευτικών πρωτεϊνών, στον οφθαλμό. Οι φαρμακοτεχνικές μορφές είναι βιοσυμβατές, βιοαποικοδομήσιμες φαρμακοτεχνικές μορφές παρατεταμένης αποδέσμευσης που περιλαμβάνουν υγρά έκδοχα χαμηλής διαλυτότητας και σχετικά μικρές ποσότητες (λιγότερο από περίπου 10%) βιοσυμβατού, βιοαποικοδομήσιμου πολυμερούς όπως τα πολυμερή PLA ή PLGA. Μία μοναδιαία δόση των 5μL έως 100μL της φαρμακοτεχνικής μορφής παρέχει παρατεταμένη αποδέσμευση του παράγοντα για τουλάχιστον 14 ημέρες.
CY20201100042T 2011-06-10 2020-01-17 Φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης για τη χορηγηση πρωτεϊνων στον οφθαλμο και μεθοδοι για την παρασκευη αυτων CY1122771T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161495672P 2011-06-10 2011-06-10
PCT/US2012/041950 WO2013036309A2 (en) 2011-06-10 2012-06-11 Sustained release formulations for delivery of proteins to the eye and methods of preparing same

Publications (1)

Publication Number Publication Date
CY1122771T1 true CY1122771T1 (el) 2021-05-05

Family

ID=47832748

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100042T CY1122771T1 (el) 2011-06-10 2020-01-17 Φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης για τη χορηγηση πρωτεϊνων στον οφθαλμο και μεθοδοι για την παρασκευη αυτων

Country Status (21)

Country Link
US (1) US9814773B2 (el)
EP (1) EP2717914B1 (el)
JP (1) JP6339011B2 (el)
KR (1) KR20140060274A (el)
CN (1) CN103945865B (el)
AU (1) AU2012304909B2 (el)
BR (1) BR112013031685B1 (el)
CA (1) CA2838289C (el)
CY (1) CY1122771T1 (el)
DK (1) DK2717914T3 (el)
ES (1) ES2761340T3 (el)
HR (1) HRP20192276T1 (el)
HU (1) HUE047737T2 (el)
IN (1) IN2013MN02384A (el)
LT (1) LT2717914T (el)
MX (1) MX359119B (el)
PL (1) PL2717914T3 (el)
PT (1) PT2717914T (el)
RS (1) RS60051B1 (el)
SI (1) SI2717914T1 (el)
WO (1) WO2013036309A2 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6530744B2 (ja) * 2013-05-24 2019-06-12 アイコン バイオサイエンス インコーポレイテッド 白内障手術後の炎症における徐放性デキサメタゾンの使用
WO2015169944A1 (en) * 2014-05-08 2015-11-12 Panoptes Pharma Ges.M.B.H. Compounds for treating ophthalmic diseases and disorders
EP3272362B1 (en) 2015-03-18 2023-12-13 Santen Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
AR105215A1 (es) * 2015-07-01 2017-09-13 Santen Pharmaceutical Co Ltd Formulación de depósito que contiene ésteres de ácido cítrico
MX2018001499A (es) * 2015-08-03 2018-08-01 Tolmar International Ltd Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.
CN116942677A (zh) 2015-09-21 2023-10-27 梯瓦制药国际有限责任公司 缓释奥氮平制剂
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
KR101957599B1 (ko) 2017-10-23 2019-03-13 김상현 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지
JP7394770B2 (ja) 2018-02-09 2023-12-08 アイコン バイオサイエンス，インコーポレイテッド 注射器から少量の用量を装填および送達するためのシステム、キット、および方法
EP3787609A4 (en) 2018-05-01 2022-01-05 Chibi, Inc. EYE DROP FORMULATION AND PROLONGED METHOD OF DRUG ADMINISTRATION TO THE RETINAL
WO2019213330A1 (en) 2018-05-01 2019-11-07 Idrop, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
US20230190657A1 (en) * 2020-05-22 2023-06-22 Trustees Of Boston University Methods and compositions for treating a fibrotic disease
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
AU2022308198A1 (en) 2021-07-06 2024-02-01 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658432B1 (fr) * 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
CA2413157A1 (en) * 2000-06-28 2002-01-03 Atul J. Shukla Biodegradable vehicles and delivery systems of biologically active substances
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
AR039729A1 (es) * 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
EP1643968A1 (en) * 2003-05-30 2006-04-12 ALZA Corporation Implantable elastomeric depot compositions, uses thereof and method of manufacturing
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
BRPI0516830A (pt) * 2004-10-01 2008-09-23 Ramscor Inc composições de droga de liberação sustentada convenientemente implantáveis
AU2005294382A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA2792484C (en) * 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
EP2269663B1 (en) * 2009-07-03 2018-03-07 Armbruster Biotechnology GmbH Bone graft and biocomposite

Also Published As

Publication number Publication date
EP2717914B1 (en) 2019-10-30
WO2013036309A2 (en) 2013-03-14
AU2012304909B2 (en) 2017-06-08
CA2838289C (en) 2019-09-10
BR112013031685B1 (pt) 2021-04-06
NZ619707A (en) 2015-01-30
ES2761340T3 (es) 2020-05-19
AU2012304909A1 (en) 2013-12-19
LT2717914T (lt) 2020-03-25
CA2838289A1 (en) 2013-03-14
MX359119B (es) 2018-09-14
MX2013014461A (es) 2014-05-14
KR20140060274A (ko) 2014-05-19
CN103945865B (zh) 2016-10-26
WO2013036309A3 (en) 2013-05-10
CN103945865A (zh) 2014-07-23
JP6339011B2 (ja) 2018-06-06
EP2717914A4 (en) 2015-05-13
BR112013031685A2 (pt) 2017-02-07
JP2014516087A (ja) 2014-07-07
HUE047737T2 (hu) 2020-05-28
EP2717914A2 (en) 2014-04-16
US9814773B2 (en) 2017-11-14
SI2717914T1 (sl) 2020-07-31
PT2717914T (pt) 2019-12-18
DK2717914T3 (da) 2020-01-20
IN2013MN02384A (el) 2015-06-12
PL2717914T3 (pl) 2020-05-18
RS60051B1 (sr) 2020-04-30
US20140140992A1 (en) 2014-05-22
HRP20192276T1 (hr) 2020-05-15

Similar Documents

Publication Publication Date Title
CY1122771T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης για τη χορηγηση πρωτεϊνων στον οφθαλμο και μεθοδοι για την παρασκευη αυτων
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1122984T1 (el) Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους
WO2016042163A3 (en) Ophthalmic drug compositions
CY1123370T1 (el) Σταθερη ενεσιμη φαρμακευτικη συνθεση ανταγωνιστη υποδοχεα νευροκινινης 1 και μεθοδος παρασκευης αυτης
CY1118232T1 (el) Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
CY1115991T1 (el) Φαρμακευτικη ψεκαζομενη συνθεση που περιλαμβανει ενα αναλογο της βιταμινης d προϊον και ενα κορτικοστεροειδες
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
EA201401348A1 (ru) Технология приготовления имплантируемой формы палиперидона
CY1118057T1 (el) Φαρμακευτικη συνθεση για στοματικη χορηγηση
BR112015011179A8 (pt) composições farmacêuticas aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas, seu uso e processos para sua preparação
IN2013DN02524A (el)
BR112012031288A2 (pt) composições
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
Rathore et al. An Overview: Matrix Tablet as Controlled Drug Delivery System.
ATE536172T1 (de) Ezetimibzusammensetzungen
BR112015024271A2 (pt) sistema de fornecimento transdérmico
CY1124512T1 (el) Εμβολια καρκινου που στοχευουν καρκινικα βλαστοκυτταρα
MY157187A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
MX2022003939A (es) Composicion farmaceutica de estabilidad mejorada.
CY1121921T1 (el) Φαρμακευτικα σκευασματα